Home › Funds › BML Capital Management, LLC › AVIR
BML Capital Management, LLC position in AVIR
ATEA PHARMACEUTICALS INC · Health Care
BML Capital Management, LLC reported holding 6,753,658 shares of AVIR (ATEA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$35.2M, representing 18.75% of its reported portfolio and ranking #2 among its reported holdings. BML Capital Management, LLC has disclosed AVIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How BML Capital Management, LLC's AVIR position evolved
BML Capital Management, LLC first disclosed a stake in AVIR in Q3 2023 at 4,800,000 shares (US$14.4M). The position peaked in Q1 2026 at 7,058,657 shares, worth US$38.0M. Across 13 filings, BML Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 6,753,658 shares valued at US$35.2M — a reduction of -198,672 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.80M | $14.40M | New |
| Q4 2023 | 5.46M | $16.66M | Add |
| Q1 2024 | 5.54M | $22.37M | Add |
| Q2 2024 | 6.38M | $21.10M | Add |
| Q3 2024 | 6.65M | $22.28M | Add |
| Q4 2024 | 7.61M | $25.49M | Add |
| Q1 2025 | 7.61M | $22.75M | Hold |
| Q2 2025 | 7.61M | $27.40M | Hold |
| Q3 2025 | 7.47M | $21.67M | Reduce |
| Q4 2025 | 7.49M | $26.74M | Hold |
| Q1 2026 | 7.06M | $37.98M | Reduce |
| Q2 2026 | 6.95M | $32.33M | Reduce |
| Q3 2026 | 6.75M | $35.19M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVIR and 13F data
AVIR (ATEA PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in AVIR — the largest reported positions include TANG CAPITAL MANAGEMENT LLC (US$22.4M), Bain Capital Life Sciences Investors, LLC (US$9.7M), Rosalind Advisors, Inc. (US$5.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVIR
- TANG CAPITAL MANAGEMENT LLC 4.81M sh · $22.39M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.08M sh · $9.65M · Q2 2026
- Rosalind Advisors, Inc. 1.07M sh · $4.98M · Q2 2026
- Royal Palms Capital LLC 71.13K sh · $2.82M · Q3 2026
- CM Management, LLC 450.00K sh · $2.34M · Q3 2026
More on BML Capital Management, LLC
FAQ
How long has BML Capital Management, LLC held AVIR?
BML Capital Management, LLC has disclosed AVIR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is BML Capital Management, LLC's current position in AVIR?
As of Q3 2026, BML Capital Management, LLC holds 6.75M shares of AVIR (ATEA PHARMACEUTICALS INC), valued at $35.19M, representing 18.75% of its reported portfolio and ranking #2.
Has BML Capital Management, LLC been buying or selling AVIR?
In the latest 13F filing (Q3 2026), BML Capital Management, LLC reduced its position in AVIR. The position peaked in Q1 2026 at 7.06M shares.
Which other funds hold AVIR?
Other major institutional holders of AVIR include TANG CAPITAL MANAGEMENT LLC, Bain Capital Life Sciences Investors, LLC, Rosalind Advisors, Inc., among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.